$Soligenix (SNGX.US)$ my opinion, DYODD

$Soligenix (SNGX.US)$ Let's wait for the next news release...

$Soligenix (SNGX.US)$
🚀🚀🚀
Can this stock run like $Phio Pharmaceuticals (PHIO.US)$  and $Salarius Pharmaceuticals (SLRX.US)$  ?

$Soligenix (SNGX.US)$ EXCLUSIVE: Soligenix Tells Benzinga 'Patients Have Responded Positively to HyBryte Therapy, With Over 70% (5 of the 6 Subjects Who Have Completed at Least 18 Weeks of Therapy) Already Achieving "Treatment Success'
EXCLUSIVE: Soligenix Tells Benzinga 'Study Supported by $2.6 Million FDA Orphan Products Development Grant'

$Soligenix (SNGX.US)$
Soligenix
Tells Benzinga HyBryte Expanded
Treatment Continues To Demonstrate Outcomes In -Early-Stage Cutaneous T-Cell Lymphoma
Tells Benzinga 'Patients have responded positively to HyBryte therapy, with over 70% (5 of the 6 subjects who have completed at least 18 weeks of therapy) already achieving "Treatment Success'
Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year
'Study Supported by $2.6 Million FDA Orphan Products Development...

$Soligenix (SNGX.US)$ Benzinga· 2 mins ago
EXCLUSIVE: Soligenix Tells Benzinga Co. Initiates Confirmatory Phase III Trial Of HyBryte For The Treatment Of Cutaneous T-Cell Lymphoma

$Soligenix (SNGX.US)$
Soligenix Tells
Benzinga Co. Initiates Confirmatory
Phase III Trial Of HyBryte For The Treatment Ot Cutaneous T-Cell
Lymphoma
Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
Monday, 16th December at 7:30 am
FLASH2 Study opens patient enrollment
PRINCETON, N.J., Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on devel...